Justis P Ehlers1, Robert Zahid2, Peter K Kaiser3, Jeffrey S Heier4, David M Brown5, Xiangyi Meng2, Jamie Reese3, Thuy K Le6, Leina Lunasco6, Ming Hu7, Sunil K Srivastava6. 1. The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio; Center for Ocular Research and Evaluation, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: ehlersj@ccf.org. 2. Novartis Pharmaceuticals, East Hanover, New Jersey. 3. Center for Ocular Research and Evaluation, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. 4. Ophthalmic Consultants of Boston, Boston, Massachusetts. 5. Retina Consultants of Houston, Houston, Texas. 6. The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio; Center for Ocular Research and Evaluation, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. 7. The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cleveland Clinic, Cleveland, Ohio; Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio.
Abstract
PURPOSE: To assess longitudinally the effect of anti-vascular endothelial growth factor (VEGF) treatment on ellipsoid zone (EZ) integrity, subretinal hyperreflective material (SHRM), and the sub-retinal pigment epithelium (sub-RPE) compartment in eyes with neovascular age-related macular degeneration (nAMD). DESIGN: Post hoc analysis of the OSPREY clinical trial, a prospective, double-masked, phase 2 study comparing brolucizumab 6 mg with aflibercept 2 mg over 56 weeks. PARTICIPANTS: Participants with treatment-naïve nAMD at the initiation of the trial were included in the analysis. METHODS: Eyes were evaluated with spectral-domain OCT at 4-week intervals in the OSPREY trial (n = 81). Spectral-domain OCT scans collected from each visit were segmented automatically using a proprietary, machine learning-enabled higher-order feature-extraction platform for retinal layer, SHRM, and sub-RPE boundary lines, which were evaluated and corrected as needed by masked trained graders. The current analysis focused only on patients evaluated with the Cirrus (Zeiss) platform (n = 28). MAIN OUTCOME MEASURES: Outcome measures included change from baseline in EZ-RPE (i.e., photoreceptor outer segment) volume, EZ-RPE central subfield thickness (CST), total EZ attenuation, SHRM volume, SHRM CST, and total sub-RPE volume. The correlation between each of these measures and best-corrected visual acuity (BCVA) at each visit was evaluated. RESULTS: EZ-RPE volume and EZ-RPE CST showed significant increases, and total EZ attenuation, SHRM volume, SHRM CST, and total sub-RPE volume showed significant decreases from baseline at each visit from weeks 4 through 56 (P < 0.05 at each visit). Ellipsoid zone integrity measures and SHRM volume correlated significantly with BCVA at most visits (P < 0.05). No significant correlation was found between total sub-RPE volume and BCVA. CONCLUSIONS: EZ integrity, SHRM, and sub-RPE disease features in eyes with nAMD showed improvement as early as week 4 of anti-VEGF treatment. EZ integrity measures and SHRM volume were predictors of visual acuity over the first year of treatment.
PURPOSE: To assess longitudinally the effect of anti-vascular endothelial growth factor (VEGF) treatment on ellipsoid zone (EZ) integrity, subretinal hyperreflective material (SHRM), and the sub-retinal pigment epithelium (sub-RPE) compartment in eyes with neovascular age-related macular degeneration (nAMD). DESIGN: Post hoc analysis of the OSPREY clinical trial, a prospective, double-masked, phase 2 study comparing brolucizumab 6 mg with aflibercept 2 mg over 56 weeks. PARTICIPANTS: Participants with treatment-naïve nAMD at the initiation of the trial were included in the analysis. METHODS: Eyes were evaluated with spectral-domain OCT at 4-week intervals in the OSPREY trial (n = 81). Spectral-domain OCT scans collected from each visit were segmented automatically using a proprietary, machine learning-enabled higher-order feature-extraction platform for retinal layer, SHRM, and sub-RPE boundary lines, which were evaluated and corrected as needed by masked trained graders. The current analysis focused only on patients evaluated with the Cirrus (Zeiss) platform (n = 28). MAIN OUTCOME MEASURES: Outcome measures included change from baseline in EZ-RPE (i.e., photoreceptor outer segment) volume, EZ-RPE central subfield thickness (CST), total EZ attenuation, SHRM volume, SHRM CST, and total sub-RPE volume. The correlation between each of these measures and best-corrected visual acuity (BCVA) at each visit was evaluated. RESULTS: EZ-RPE volume and EZ-RPE CST showed significant increases, and total EZ attenuation, SHRM volume, SHRM CST, and total sub-RPE volume showed significant decreases from baseline at each visit from weeks 4 through 56 (P < 0.05 at each visit). Ellipsoid zone integrity measures and SHRM volume correlated significantly with BCVA at most visits (P < 0.05). No significant correlation was found between total sub-RPE volume and BCVA. CONCLUSIONS: EZ integrity, SHRM, and sub-RPE disease features in eyes with nAMD showed improvement as early as week 4 of anti-VEGF treatment. EZ integrity measures and SHRM volume were predictors of visual acuity over the first year of treatment.
Authors: Sharif El-Emam; Jay Chhablani; Giulio Barteselli; Haiyan Wang; Su Na Lee; Igor Kozak; Lingyun Cheng; William R Freeman Journal: Retina Date: 2013-06 Impact factor: 4.256
Authors: Sophie Riedl; Lewis Cooney; Christoph Grechenig; Amir Sadeghipour; Eleonore Pablik; John W Seaman; Sebastian M Waldstein; Ursula Schmidt-Erfurth Journal: Retina Date: 2020-11 Impact factor: 4.256
Authors: Alex S Willoughby; Gui-Shuang Ying; Cynthia A Toth; Maureen G Maguire; Russell E Burns; Juan E Grunwald; Ebenezer Daniel; Glenn J Jaffe Journal: Ophthalmology Date: 2015-07-02 Impact factor: 12.079
Authors: Pearse A Keane; Praveen J Patel; Yanling Ouyang; Fred K Chen; Felicia Ikeji; Alexander C Walsh; Adnan Tufail; Srinivas R Sadda Journal: Invest Ophthalmol Vis Sci Date: 2010-06-16 Impact factor: 4.799
Authors: Sruthi Arepalli; Charles C Wykoff; Joseph R Abraham; Leina Lunasco; Hannah Yu; Ming Hu; Sunil K Srivastava; Jamie L Reese; David Brown; Justis P Ehlers Journal: Eye (Lond) Date: 2022-10-11 Impact factor: 4.456
Authors: Tisileli S Tuifua; Joseph R Abraham; Sunil K Srivastava; Peter K Kaiser; Jamie Reese; Justis P Ehlers Journal: Retina Date: 2022-02-01 Impact factor: 4.256